Expert Review of Pharmacoeconomics & Outcomes Research

Article	Citations
Social care data in the UK; current landscape, challenges, and future recommendations	37
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	32
Adherence to augmentation therapy for the treatment of major depressive disorder	30
Indication-based pricing of the pharmaceuticals in Croatia: case-study	24
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	23
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	22
How to create value with constrained budgets in oncological care? A narrative review	20
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	17
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations	17
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	16
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	15
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	14
Consumption of antidepressants and economic austerity in Brazil	12
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	12
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review	11
The role of insurance policies in the drug pricing landscape	11
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	10
The impact of under-investment on health in Southern and Central Eastern European Countries	10
A methodological guide for implementing and interpreting results of probabilistic analysis	10
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	10
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	9
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	9
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	9
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	9
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	9

Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	9
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	9
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture	9
The impact of bone turnover marker on medication adherence and the health economics-related consequences	9
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	8
An update on the economic burden of type 2 diabetes mellitus in China	8
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	8
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	8
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	8
Systematic reviews of machine learning in healthcare: a literature review	8
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	8
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	8
Digital measures in epilepsy in low-resourced environments	8
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	8
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	7
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	7
How relevant is the BMI for cost-of-illness studies in the 21st century?	7
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	7
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation	7
Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination	7
Developing the Lebanese health economic evaluation guideline	7
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	7
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	7
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	7
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	7
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	6
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care	6
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	6
Burden of disease of chronic pain in Ecuador	6
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	6
Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework	6
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama	6
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	6
Valuing prevention: lessons and recommendations from a Dutch expert committee	6
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy	6
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	6
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries	6
Bridging the gap: enhancing medication adherence through research and innovation	6
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies	6
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	6
Systematic review on the use of cost-benefit analysis to evaluate food environment interventions	6
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	6
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	6
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	6
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	6
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair	6
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Economic benefits of global Collaborative Health technology	5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review	5
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	5

Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	5
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	5
A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study	5
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	5
The hidden burden of atopic dermatitis in central and Eastern European countries	5
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	5
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	5
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	4
The economic impact of pharmacist intervention during pandemics	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	4
Correction	4
The economics of prevention and quality of care: policy insights from the EU’s COVID-19 response	4
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	4
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	4
Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands	4
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	4
The Lebanese health economic evaluation guideline	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	4
Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019–2025): a systematic review	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	4
Digital decision aids and prenatal outcomes: a systematic review and meta-analysis	4
The health production model and the crucial role of health promotion	3
Burden of disease of chronic pain in Colombia	3
Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina	3
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
Budget impact of low-dose computed tomography screening for lung cancer in Argentina	3
Perspectives in prospective comparative economic evaluations: a systematic review	3
Barriers to digital endpoints in data collection in low and middle-income countries	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves	3
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	3
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	3
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia	3
Pharmacovigilance and outcomes: experience from Saudi Arabia narrative review	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
Cost-utility analysis of Lenvatinib vs. Sorafenib in unresectable hepatocellular carcinoma in Iran	3
Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program	3
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	3
Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review	3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds	3
Public value judgments about the criteria for reimbursement of medicines in South Korea	3
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	3
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol	3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024	3
Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review	3
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare	3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	3
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
The short-term impact of copayment reductions for government subsidised medicines in Australia	3
Implementing a Managed Entry Agreement Framework in Cyprus	3
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	3
Correction	2
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and high-sales biosimilars	2
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	2
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	2
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	2
Cost-effectiveness of durvalumab with or without olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer	2

The utility and impact of digital endpoints for improving breast cancer outcomes	2
What to expect in 2024: important health economics and outcomes research (HEOR) trends	2
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	2
Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990–2022	2
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	2
Payer and Developer perspectives on alternative payment models	2
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	2
How should we measure the use of social care and informal care?	2
How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions	2
An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis	2
The economic benefits of fracture prevention	2
A review of caregiver costs included in cost-of-illness studies	2
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	2
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	2
Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors	2
Proposed method for economic evaluation based on basket trials: a case study of pembrolizumab	2
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	2
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	2
How unprofessional behaviours between healthcare staff threaten patient care and safety	2
Cost–utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain	2
Integrated care in Western Europe: a wise solution for the future?	2
Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step	2
A landscape analysis and discussion of value of gene therapies for sickle cell disease	2
Diabetes disparities in diabetes health care access and outcomes during the COVID-19 pandemic in the United States	2
Direct healthcare costs for people with cerebral palsy in the Brazilian unified health system between 2015 and 2019	2
The impact of non-pharmacological interventions on adherence to medication and persistence in dyslipidaemia and hypertension: a systematic review	2
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs	2
Willingness to pay for a quality-adjusted life year (QALY) in Pakistan: implications for health policy	2
Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study	2
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	2
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health	2
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	2
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis	2
Advancing the economics of prevention: emerging methods and approaches	2
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	2
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Sing	2
The cost-of-illness of multiple sclerosis in Jordan	2
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	2
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	2
Economic evaluation of clinical pharmacy service using integrated health system in tertiary care hospital	2
Economic burden of suicides and suicide attempts in low- and middle-income countries: a systematic review of costing studies	2
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc)	2
Willingness to pay for cancer prevention versus treatment in China: implications for cost-effectiveness threshold	1
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension	1
Use of the incremental cost-effectiveness ratio for decision-making policies—what is the problem? A perspective paper	1
Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach	1
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspe	1
Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia	1
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?	1
Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update	1
Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review	1
All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain	1
A cost-effectiveness analysis of pharmacotherapy versus prostatic urethral lift as initial therapy for patients with moderate benign prostatic hyperplasia	1
Medical oncologists’ dance with international guidelines and national reimbursement: insights from a survey in Türkiye	1
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies	1
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore	1
A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany	1
Present challenges impacting the management of psychological symptoms in patients receiving CAR-T therapy or stem cell transplantation	1
Nonadherence to antiseizure medications: what have we learned and what can be done next?	1
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	1
Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy – a multi-center observational study within the CFHealthHub learning health system	1
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer	1
The evolution and future of integrated evidence planning	1
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China	1
Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis	1
Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study	1
Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting	1
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework	1
A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom	1
Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy	1
Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review	1
Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities	1
Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study	1
Oxygen saturation thresholds for bronchiolitis at high altitudes: a cost-effectiveness analysis	1
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	1
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	1
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	1
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder	1
Assessing smoking cessation services and pharmacotherapy in Namibia: findings and implications for future policy initiatives	1
Budget impact of lecanemab for medicare beneficiaries with early Alzheimer’s disease in the United States: a subgroup analysis	1
Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis	1
Next-generation sequencing in oncology: challenges in economic evaluations	1
Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China	1
HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework	1
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	1
Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population	1
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023	1
Acceptability and willingness to pay for a hypothetical HIV vaccine in Brazil and the implications: a cross-sectional study	1
Learnings from cross-border biosimilar pricing policies in Europe	1
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events	1
A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer	1
Meta-analysis of traditional Chinese medicine on chronic kidney disease	1
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	1
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review	1
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	1